Dessolve III - Study Purpose


Study objective 

To compare the MiStent with the XIENCE with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a “real world” patient population.

Primary endpoint

The primary endpoint for this trial is a non-inferiority comparison of a device-oriented composite endpoint (DOCE) or TLF of the MiStent group to the XIENCE group at 12 months post-procedure. TLF is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically-indicated target lesion revascularization (TLR).